Physician profile
Amy Santangelo
NPI 1841254711
$2,565.48
in general payments reported to CMS, 2019-2025
24 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $755 · 2024: $777 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $383.91 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $382.70 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $314.61 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $195.90 | 2023-2025 | Repatha, Evenity, Prolia |
| Radius Health, INC. | $191.76 | 2024-2025 | Tymlos |
| Pfizer INC. | $162.33 | 2023-2025 | |
| Abbvie INC. | $162.02 | 2023-2025 | Qulipta, Ubrelvy |
| Abbott Laboratories | $143.43 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $105.92 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $91.24 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.10 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $63.33 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $42.21 | 2023-2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $34.28 | 2023-2024 | Contrave, Onzetra Xsail |
| Phathom Pharmaceuticals, INC. | $28.85 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.01 | 2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.09 | 2024 | Trulance, Xifaxan |
| Dexcom, INC. | $21.42 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $21.06 | 2024 | Auvelity |
| Scilex Pharmaceuticals INC. | $18.59 | 2024 | |
| Astellas Pharma US INC | $18.46 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $18.06 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
| Bausch Health US, LLC | $15.57 | 2025 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Santangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.